Industry Portals
Pharmaceutical Industry News
Integer a velit nec risus malesuada imperdiet id et odio. Nunc sit amet mauris dapibus, feugiat diam eget, suscipit, nam gravida nulla eget turpis commodo.
Chemical Financing Activity Mixed (ICIS Chemical Business August 7 – August 13, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of financing trends in the first half of 2026 and the future outlook in 2026.
A Survey of Senior Chemical Industry Executives
Young & Partners shares with our analysis of the current and future sentiment and outlook of chemical industry executives in 2026.
Chemical M&A Surges (ICIS Chemical Business July 31, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of M&A trends in 2025 and the future outlook in 2026.
Cautious Momentum: Biopharma Review and Outlook (Pharmaceutical Executive March 2026)
Young & Partners shares with Pharmaceutical Executive on our analysis of M&A trends for Pharmaceuticals and Biotech in 2025 and the future outlook of M&A in 2026.
Chemicals M&A To See Upturn in 2026 (Chemical Week Feb 2 – Feb 9, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of M&A trends in 2025 and the future outlook in 2026.
The Good, The Bad, and the Ugly (ICIS Chemical Business Jan 30 – Feb 5, 2026)
Young & Partners reports on our analysis of chemical stock market and financing trends for 2025 and the future outlook in 2026.
Signs of Revival in Chemical M&A (ICIS Chemical Business Jan 23 – Jan 29, 2026)
Young & Partners reports on our analysis of M&A markets for 2025 and the future outlook for Chemical M&A.
Pharmaceutical Executive Academy: The Impact of AI on the Life Science Industry with Najat Khan
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners
Financing Markets Mixed, Equities Lag (ICIS Chemical Business Nov 27 – Dec 4, 2025)
Young & Partners reports on our analysis of the debt and equity financing markets for the first three quarters of 2025 and the future outlook for Chemical financings.
Chemical M&A Mixed, Sideways (ICIS Chemical Business Nov 21 – Nov 27, 2025)
Young & Partners reports on our analysis of the M&A markets for the first three quarters of 2025 and the future outlook for Chemical M&A.
Young & Partners 2025 Pharmaceutical Executive Summit: Will China Overtake the West in Drug Development?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners
Young & Partners 2025 Pharmaceutical Executive Summit: Fireside Chat with Dr. William Pao, author of “Breakthrough: The Quest for Life-Changing Medicines
William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer
Young & Partners 2025 Pharmaceutical Executive Summit: Doug Long The Pharmaceutical Market: Trends, Issues and Outlook
Doug Long, Vice President, Industry Relations, IQVIA
Young & Partners 2025 Pharmaceutical Executive Summit: Najat Khan Latest Developments in Artificial Intelligence
Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals, Former Chief Data Science Officer & Global Head, Strategy & Portfolio Organization, Innovative Medicine R&D, Johnson & Johnson
Young & Partners 2025 Pharmaceutical Executive Summit: Michael Christel, Fred Hassan Commercialization: Why are Success Rates Falling?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Fred Hassan, Director, Warburg Pincus, Former CEO of Schering Plough and Former CEO of Pharmacia
Young & Partners 2025 Pharmaceutical Executive Summit: William Pao, Paul Sekhri The Changing Roles and Relationships – Biotech and Pharma
William Pao, CEO, Revelio Therapeutics, Inc., Former Head of R&D, Pfizer Paul Sekhri, President and CEO, vTv Therapeutics
Navigating Divergent Currents – Biopharma Review and Outlook (Pharmaceutical Executive, August 2025)
Young & Partners shares proprietary analysis of the M&A, stock market, and funding environment in Biotech and Pharma and the outlook for 2025.
Young & Partners Forum Series: The Energy Transition and its Implications- Jason Bordoff of Columbia University SIPA
Jason Bordoff, Founding Director of the Center on Global Energy Policy, Columbia University SIPA; Previously Special Assistant to President Barack Obama and Senior Director for Energy and Climate Change, the Staff of the National Security Council Peter Young, President and CEO, Young & Partners